Dr. Carol H. Wysham interviews AACE President, Scott D. Isaacs, MD, FACP, FACE, on the Medscape InDiscussion: Type 2 Diabetes (Season 3) podcast to discuss the screening and management of…
Eli Lilly has reduced the prices of certain Zepbound vials and introduced higher-dose options, making the weight-loss drug more accessible. AACE President Scott D. Isaacs, MD, FACP, FACE, and AACE…
Machine learning may help identify biomarkers and develop predictive models that could assist in the diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD) and hepatic fibrosis…
AACE Patient Journey of Diabetes Technology Quiz
Test your diabetes technology knowledge with this 10-question quiz.
Begin by choosing an answer option, and then click "…
Thank You!
Thank you for sharing your feedback with us. Your input is truly valued, as it plays a vital role in shaping the future of AACE patient journeys.
…
AACE President, Scott D. Isaacs, MD, FACP, FACE, highlights key opportunities for health care professionals to expand their medical knowledge through AACE’s latest initiatives, including the 2025…
Listen to episode #481 of The Curbsiders Internal Medicine Podcast, featuring AACE President, Scott D. Isaacs, MD, FACP, FACE, as he shares essential pearls on navigating screening tests for diabetes…
The 2025 Consensus Statement on the Management of Multiple Endocrine Neoplasia Type 1 (MEN1) has been published in Endocrine Practice. Dr. Jaydira Del Rivero, Chair of the MEN1 Consensus…
Ozempic feet are characterized by sagging skin and reduced fat padding in the feet, which can occur with rapid weight loss. AACE President Scott D. Isaacs, MD, FACP, FACE, and AACE member Karl…